MARGINAL ZONE LYMPHOMA
Clinical trials for MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study had two parts: one to determine t…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis study tested an experimental pill called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for lymphoma patients: drug cocktail shows promise in early trial
Disease control CompletedThis study tested a combination of drugs called VR-CAP as a first treatment for people with marginal zone lymphoma, a type of blood cancer. 26 patients received the therapy to see how well it controlled the disease and how safe it was. The main goal was to measure how many patien…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or combined with other drugs (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to find a safe dose and check for side effects. Re…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for lymphoma patients who can't handle standard drugs
Disease control CompletedThis study looked at a drug called zanubrutinib for people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had to stop taking similar drugs (ibrutinib or acalabrutinib) because of bad side effects. The main goal was to see if …
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Engineered immune cells shrink tumors in Hard-to-Treat lymphoma
Disease control CompletedThis study tested a one-time treatment called axicabtagene ciloleucel (a CAR T-cell therapy) in 159 adults with follicular or marginal zone lymphoma that had not responded to at least two prior treatments. The therapy works by reprogramming a patient's own immune cells to attack …
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New cancer drug combo shows promise but doses remain uncertain
Disease control CompletedThis study tested a new drug (BGB-10188) alone or with other drugs in 97 people with certain blood cancers or advanced solid tumors. The goal was to find the safest and most effective dose. However, the best dose could not be determined for all groups because not enough data was …
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug combo may make Half-Matched transplants safer for blood cancer patients
Disease control CompletedThis study tested whether replacing a standard transplant drug (cyclophosphamide) with a different drug (bendamustine) could make half-matched bone marrow transplants safer for people with blood cancers like leukemia and lymphoma. About 50 patients took part. The goal was to redu…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated May 01, 2026 15:57 UTC